Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microdosing to individualize docetaxel dosing
2016-003785-77Phase 4Terminated
- Start
- Oct 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of docetaxel in breast cancer, prostate cancer (PCa) and non-small cell lung cancer (NSCLC). Primary endpoint: Primary pharmacokinetic relationship between microdose and therapeutic dose docetaxel. Started Oct 2016; status: terminated.
02
Drugs
docetaxel
03
Conditions
breast cancerprostate cancer (PCa)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2016-003785-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003785-77.